ReviewSurgical neurology international2026
A systematic review of the utility of 5-aminolevulinic acid-induced fluorescence in spine tumor surgery.
Review in Surgical neurology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: 5-aminolevulinic acid (5-ALA)-induced fluorescence is well established in intracranial glioma surgery, aiding tumor visualization and extent of resection. This systematic review evaluates the utility of 5-ALA in spinal tumor surgery, focusing on fluorescence characteristics, resection outcomes, and perioperative safety. Methods: A systematic literature search was performed in Embase, Web of Science, PubMed, and MEDLINE databases; 13 studies met the inclusion criteria. Eligible studies involved human subjects undergoing spinal tumor surgery with intraoperative use of 5-ALA for tumor fluorescence. Primary outcomes assessed included fluorescence response and extent of resection; secondary outcomes included postoperative neurological status and adverse effects. Results: Thirteen studies involved 245 patients whose tumor diagnoses included ependymomas, meningiomas, astrocytomas, neurinomas, and metastatic lesions. Fluorescence rates varied by tumor type; uptake showed high positivity in ependymomas and meningiomas, but inconsistent findings for astrocytomas and metastases. Gross total resection was achieved more frequently in well-circumscribed benign tumors. Although patients experienced favorable postoperative outcomes, transient or persistent neurological deficits occurred in a subset of patients depending on tumor location and surgical complexity. Standard dosing (20 mg/kg preoperatively) was consistent across studies, and adverse effects were limited to expected photosensitivity. Conclusion: 5-ALA enhances intraoperative visualization and may facilitate more complete resection of selected spinal tumors, particularly ependymomas and meningiomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.